Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Latest Media Coverage
Nature Reviews Drug Discovery
FDA new drug approvals in Q1 2020
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
New York Times
Pharmaceutical Profits and Public Health Are Not Incompatible
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Browse the archive
The Pharma Letter
Look back at pharma news in the week to October 4
Doptelet could be worth more to the Swedish group, according to EvaluatePharma's NPV analyser.
Handelsblatt
Sartorius Group relies on aging population and better health care
These so-called biosimilars also require products such as those manufactured by Sartorius or major competitors such as Thermo Fischer, Danaher, Merck Millipore or GE. In…
MedCity News
Cigna creates new program to pay for high-price gene therapies
Meanwhile, Novartis gave Zolgensma a list price of more than $2 million, making it the most expensive drug ever. Cigna cited figures from EvaluatePharma indicating that…
El Global
The sector is experiencing the biggest decline in mergers and acquisitions of the last decade
Although so far this year the sector accumulates a total of 173,000 million dollars in mergers or acquisitions, the truth is that the total number of transactions shows a…
Investor's Business Daily
Can Biosimilars Take On $198 Billion In Blockbuster Drug Sales?
There's $198 billion up for grabs as patents expire between 2019 and 2024, according to a June report from research firm Evaluate Pharma.
Wall Street Journal
Insurers Pitch New Ways to Pay for Million-Dollar Therapies
Insurers are scrambling to blunt the expense of new drugs that can carry prices of more than $2 million per treatment, offering new setups aimed at making the cost of…
Neue Zürcher Zeitung
Novartis curbs expectations on gene and cell therapies - is that the actual assessment, or is it bluff?
Moran cited a forecast by market research firm Evaluate Pharma that the total market for gene and cell therapies would only reach $ 14 billion by 2024.
The Pharma Letter
Mixed results for Novartis’ Entresto presented at ESC
Novartis is sticking to its guns. Despite the overall failure of the PARAGON trial of Entresto in heart failure with preserved ejection fraction (HFpEF), the company…
The Pharma Letter
Look back at pharma news in the week to August 30
In paying $25 million up front to license Ionis Pharmaceuticals’ chronic hepatitis B antisense therapies GlaxoSmithKline looks to have cut a better deal than Johnson…
FiercePharma
ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe
Results such as those have helped Eliquis surge past its non-VKA competitors but also top warfarin in market share. Its commanding lead could put Eliquis’ peak sales at…
